AstraZeneca’s Etcamah misses late-stage trial goal in breast cancer
AI Summary- AstraZeneca said Etcamah failed to slow advanced breast cancer in a late-stage trial.
- AstraZeneca shares fell 0.43%, while Pfizer shares rose 0.25%.
- Etcamah was tested with Pfizer’s Ibrance as a first-line treatment for untreated advanced disease.